Ir para o conteúdo
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Inability to Tolerate Standard...
  • Citar
  • Enviar por SMS
  • Enviar por email
  • Imprimir
  • Exportar registo
    • Exportar para RefWorks
    • Exportar para EndNoteWeb
    • Exportar para EndNote
  • Permanent link
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial

Show other versions (2)
Detalhes bibliográficos
Main Authors: Sive, J, Buck, G, Fielding, A, Lazarus, H, Litzow, MR, Luger, S, Marks, D, McMillan, A, Richards, S, Rowe, J, Tallman, MS, Goldstone, A
Formato: Conference item
Publicado em: 2010
  • Exemplares
  • Descrição
  • Other Versions (2)
  • Registos relacionados
  • Registo fonte
Descrição
Resumo:

Registos relacionados

  • Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
    Por: Sive, J, et al.
    Publicado em: (2010)
  • Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
    Por: Sive, J, et al.
    Publicado em: (2010)
  • Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
    Por: Sive, J, et al.
    Publicado em: (2012)
  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
    Por: Fielding, A, et al.
    Publicado em: (2007)
  • Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
    Por: Fielding, A, et al.
    Publicado em: (2010)

Opções de Pesquisa

  • Histórico de Pesquisas
  • Pesquisa Avançada

Encontrar Mais

  • Percorrer o Catálogo
  • Percorrer por ordem alfabética
  • Explore Channels
  • Bibliografia Recomendada
  • Novos exemplares

Precisa de ajuda?

  • Dicas de Pesquisa
  • Serviço de Referência
  • FAQs